Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota capsule
- Development stage
- Phase 1
- Lead developer
- Zhongshan Hospital, Xiamen University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Fecal microbiota capsule (Zhongshan Hospital Xiamen University) is an oral microbial therapy being investigated for the treatment of inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. The product consists of standardized fecal microbiota extracted from healthy donors and delivered in capsule form. It functions by restoring the diversity and balance of the recipient's intestinal microbiome, which is typically disrupted (dysbiosis) in patients with IBD. By re-establishing a healthy microbial community, the therapy aims to modulate the mucosal immune system and reduce intestinal inflammation. This specific formulation is being evaluated in clinical trials led by Zhongshan Hospital of Xiamen University to determine its efficacy, safety, and durability in patients who may not respond to traditional IBD treatments.
- Other names
- fecal microbiota capsulestandardized fecal microbiota transplantationFMT capsule
Beyond the preview
Go deeper on fecal microbiota capsule.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota capsule.